

**ABSTARCT**

5

A method of stabilizing and potentiating action of molecules of known  
anti-angiogenic substances such as Angiostatin<sup>®</sup> or Endostatin<sup>®</sup> by using in  
coupling conjugation with cis-unsaturated fatty acids (c-UFAs) in the  
treatment of cell proliferative disorders uses c-UFAs chosen from linoleic  
acid, gamma-linolenic acid, dihomogamma-linolenic acid, arachidonic acid,  
alpha-linolenic acid, eicosapentaenoic acid, docosahexaenoic acid and cis-  
parinaric acid in predetermined quantities. Preferably, the c-UFAs are in the  
form of polyunsaturated fatty acids (PUFAs). Uncontrolled or undesirable  
angiogenic activity promotes cell proliferative disorders and tumor growth,  
which can be inhibited by the selective use of PUFAs with anti-angiogenic  
substances used selectively in conjunction with predetermined anti-cancer  
drugs. For a non-glioma type of cell proliferation disorder, a sodium,  
potassium or lithium salt of a PUFA is preferred to form an admixture with  
an anti-angiogenic substance. Anti-angiogenic substances envisaged in this

35

40

invention include Angiostatin<sup>®</sup>, Endostatin<sup>®</sup>, platelet factor-4, TNP-470, thalidomide, interleukin-12 and metalloproteinase inhibitors (MMP). A preferred method of administration of the mixture to treat a tumor is intra-arterial administration into an artery which provides the main blood supply for the tumor.